Sugi Predict

Sugi Predict / Compounds / SCHEMBL1788930

SCHEMBL1788930

SCHEMBL1788930

COc1cccc(NC(=O)Nc2cccc(-c3nc4ccccn4c3-c3ccnc(Nc4cccc(N5CCOCC5)c4)n3)c2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 4/20 0.62
▸ CDK19 Q9BWU1 2/20 0.62
▸ IGF1R P08069 13/20 0.61
▸ EGFR P00533 9/20 0.61
▸ ERBB2 P04626 9/20 0.61
▸ LCK P06239 6/20 0.59
▸ KDR P35968 6/20 0.59
▸ AURKB Q96GD4 6/20 0.59
▸ MAP4K5 Q9Y4K4 6/20 0.59
▸ STK3 Q13188 5/20 0.59
▸ PRKD3 O94806 4/20 0.59
▸ FGFR1 P11362 4/20 0.59
▸ SYK P43405 4/20 0.59
▸ TAOK1 Q7L7X3 4/20 0.59
▸ SLK Q9H2G2 4/20 0.59
▸ MAP3K20 Q9NYL2 4/20 0.59
▸ CSF1R P07333 4/20 0.59
▸ RET P07949 4/20 0.59
▸ INSR P06213 4/20 0.59
▸ SRC P12931 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1789167 0.92 IGF1R (0.71) PTK2IGF1REGFRERBB2LCK
SCHEMBL1789150 0.90 IGF1R (0.67) PTK2CDK19IGF1REGFRERBB2
SCHEMBL1789148 0.89 IGF1R (0.61) PTK2CDK19IGF1REGFRERBB2
SCHEMBL1790887 0.89 IGF1R (0.61) PTK2CDK19IGF1REGFRERBB2
SCHEMBL1791539 0.88 BRAF (0.70) PTK2CDK19IGF1REGFRERBB2
SCHEMBL1871349 0.88 IGF1R (0.64) PTK2CDK19IGF1REGFRERBB2
SCHEMBL1788491 0.88 IGF1R (0.61) PTK2CDK19IGF1REGFRERBB2
SCHEMBL1791811 0.86 IGF1R (0.66) PTK2IGF1REGFRERBB2LCK
SCHEMBL1788634 0.86 IGF1R (0.62) PTK2IGF1REGFRERBB2LCK
SCHEMBL1791235 0.85 IGF1R (0.79) PTK2CDK19IGF1REGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051315-B2 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition ABBVIE INC. (US) 2015-06-09 — — US claimed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 — — US claimed
US-9051315-B2 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition ABBVIE INC. (US) 2015-06-09 — — US disclosed
EP-2496574-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION Abbott Laboratories (US) 2012-09-12 — — EP disclosed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 — — US disclosed
WO-2011053476-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION PACSIN2, MAP4K2, MAP3K6 PTK2 107/4885CDK19 522/4885IGF1R 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.